ArticleOncoTargets and therapy2012
Targeted treatments for cervical cancer: a review.
Article in OncoTargets and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 90 citations in OpenAlex.
- Enhanced targeted treatment of cervical cancer using nanoparticle-based doxycycline delivery system.Scientific reports · 2025Article
- Surgical Advancements, Immunotherapy, Targeted and Conventional Therapies, Biopsy, Colposcopy, and Pap Smear Integration in the Management of Cervical Cancer.Current medicinal chemistry · 2025Review
- The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers.Frontiers in immunology · 2024Review
- Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.Medical oncology (Northwood, London, England) · 2023Review
- Human papillomavirus infection, cervical cancer and the less explored role of trace elements.Biological trace element research · 2023Review
- Activating transcription factor 3 inhibits NF‑κB p65 signaling pathway and mediates apoptosis and cell cycle arrest in cervical cancer cells.Infectious agents and cancer · 2022Article
- Cervical cancer therapies: Current challenges and future perspectives.Tumour virus research · 2022Review
- Anticancer Potential of L-Histidine-Capped Silver Nanoparticles against Human Cervical Cancer Cells (SiHA).Nanomaterials (Basel, Switzerland) · 2021Article
- Synthesis and Characterization of Mannosylated Formulations to Deliver a Minicircle DNA Vaccine.Pharmaceutics · 2021Article
- Long non-coding RNA RP11-284F21.9 functions as a ceRNA regulating PPWD1 by competitively binding to miR-769-3p in cervical carcinoma.Bioscience reports · 2020Article
- Neferine, an alkaloid from lotus seed embryo targets HeLa and SiHa cervical cancer cells via pro-oxidant anticancer mechanism.Phytotherapy research : PTR · 2020Article
- Antitumor Activity and Mechanism Study of Riluzole and Its Derivatives.Iranian journal of pharmaceutical research : IJPR · 2020Article
- Prediction of High-Risk Types of Human Papillomaviruses Using Reduced Amino Acid Modes.Computational and mathematical methods in medicine · 2020Article
- Immunotherapy for HPV associated cancer.Papillomavirus research (Amsterdam, Netherlands) · 2019Review
- HPV16-transformed human keratinocytes depend on SIX1 expression for proliferation and HPV E6/E7 gene expression.Virology · 2019Article
- Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer.Translational oncology · 2019Article
- Whole-exome and RNA sequencing reveal novel insights into the pathogenesis of HPV associated cervical cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Biodegradable andrographolide-eluting nanofibrous membranes for the treatment of cervical cancer.International journal of nanomedicine · 2019Article
- Dynamic influence of Rhein lysinate on HeLa cells.International journal of oncology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%-95% of women with early stage cancer, the recurrent and metastatic disease remains a major cause of cancer death. Many efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent decades, research on treatment strategies has proposed several options, including the role of HPV E6 and E7 oncogenes, which are retained and expressed in most cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cellular cycle control, perturbation of antitumor immune response, alteration of gene expression, and deregulation of microRNA expression. Thus, in this review article we discuss potential targets for the treatment of cervical cancer associated with HPV infection, with special attention to immunotherapy approaches, clinical trials, siRNA molecules, and their implications as gene therapy strategies against cervical cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.